View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
November 17, 2020

Coronavirus company news summary – Moderna publishes early efficacy data for Covid-19 vaccine – Lilly and Samsung Biologics sign long-term production agreement

By Allie Nawrat

17 November 2020

Moderna announced that its mRNA-1273 Covid-19 vaccine candidate met its primary efficacy endpoint according to the first interim data from a Phase III study. The interim data showed that mRNA-1273 had an efficacy rate of 94.5% based on 95 cases of Covid-19. More than 30,000 participants in the US are enrolled in the study, which is being conducted with the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority. 

Samsung Biologics announced that it has struck a long-term deal with Eli Lilly to produce the antibody-drug neutralising Covid-19. The Korean-based biotech signed a contract manufacturing organisation agreement with the US pharmaceutical company in May to supply the drug for Covid-19.

Bharat Biotech has begun Phase III trials of Covaxin, its Covid-19 vaccine candidate in India. The trial involves 26,000 participants across 22 locations and will be conducted in collaboration with the Indian Council of Medical Research. The trial has been approved by the Drugs Controller General of India and registered with the clinical trials registry of India.

TrippBio is currently developing a US Food and Drug Administration (FDA)-approved drug called TD213 for treating mild and moderate Covid-19 infections. The orally administered drug blocks the replication of the SARS-CoV-2 virus and associated acute inflammatory conditions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology